Victori Pharma-B (09887.HK): The first subject in the Phase I trial of LBL-047 received medication.

Zhixin Finance APP news, Willebe Bro-B (09887.HK) issued an announcement, the first subject of the Phase I clinical study evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical efficacy of LBL-047 has successfully received the drug.